Catalog No.
PHH48401
Species reactivity
Human
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human MPEG1 (Phe313-Ser580).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:200, WB: 1:500-1:4000
Target
Macrophage-expressed gene 1 protein,Perforin-2,Mpg-1,MPEG1,P-2,Macrophage gene 1 protein
Concentration
0.74 mg/ml
Purification
Purified by antigen affinity column.
Accession
Q2M385
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
The current and emerging immunotherapy paradigm in small-cell lung cancer., PMID:40473974
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial., PMID:40450142
Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial., PMID:40450141
Solution structure and synaptic analyses reveal determinants of bispecific T cell engager potency., PMID:40445758
Prognostic Value of the G2 Expression Signature and MYC Overexpression in Childhood High-Grade Osteosarcoma., PMID:40440582
Lower baseline amyloid beta burden is associated with greater percent of amyloid beta positron emission tomography reduction and better clinical outcomes in the aducanumab Phase 3 trials ENGAGE and EMERGE in early Alzheimer's disease., PMID:40413110
Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial., PMID:40341383
Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study., PMID:40339592
Preparation of chitosan-derived hierarchical porous materials and study on their adsorption of patulin., PMID:40328201
TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer., PMID:40297626
Uncovering cell cycle-dependent effects on cell survival in near-infrared photoimmunotherapy., PMID:40273966
Error-corrected flow-based sequencing at whole-genome scale and its application to circulating cell-free DNA profiling., PMID:40217113
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study., PMID:40198940
Identification of biomarkers of shrinkage modes after neoadjuvant therapy in HER-2 positive breast cancer., PMID:40143733
Nausea and vomiting in an evolving anticancer treatment landscape: long-delayed and emetogenic antibody-drug conjugates., PMID:40105595
Immunoelectrochemical assessment of human IgE in non-invasive samples of allergic individuals using PdNCs-labelled antibodies., PMID:40100481
Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer., PMID:40081941
A high-density 4-vinylpyridine membrane for rapid purification of antibodies., PMID:40062412
Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies., PMID:40054461
Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) Patients., PMID:40021433
Successful treatment of immune checkpoint inhibitor-associated fulminant myocarditis with abatacept and ruxolitinib: a case report., PMID:39963309
Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study., PMID:39916320
Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial., PMID:39893343
Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer., PMID:39876075
Pre-Clinical Rationale for Amcenestrant Combinations in HER2+/ER+ Breast Cancer., PMID:39859174
Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas., PMID:39846804
[Short-term efficacy of rituximab in children with calcineurin inhibitor resistant steroid resistant nephrotic syndrome]., PMID:39844495
Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial., PMID:39838118
Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trial., PMID:39838117
A phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendocrine tumors., PMID:39834129
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial., PMID:39825152
Plasma levels of anti phosphocholine IgM antibodies are negatively correlated with bone mineral density in humans., PMID:39814831
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer., PMID:39778121
A trial of radiolabeled antibody yttrium-90-FF-21101 for the treatment of advanced ovarian and other cancers., PMID:39748726
Proteolysis targeting chimera (PROTAC)-driven antibody internalization of oncogenic cell surface receptors., PMID:39741170
Preparation of chitin-derived hierarchical porous materials and their application and mechanism in adsorption of mycotoxins., PMID:39722398
Selective IgM deficiency: evaluation of 75 patients according to different diagnostic criteria., PMID:39680289
Skin autonomous antibody production regulates host-microbiota interactions., PMID:39662506
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors., PMID:39637943
Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade., PMID:39577421
Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non-Small Cell Lung Cancer., PMID:39576208
ImmunoCellCycle-ID - a high-precision immunofluorescence-based method for cell cycle identification., PMID:39564775
Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid Tumors., PMID:39560862
Extracellular vesicles containing SARS-CoV-2 proteins are associated with multi-organ dysfunction and worse outcomes in patients with severe COVID-19., PMID:39558820
Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial., PMID:39551064
Enhanced Prenatal and Postnatal Development Study in Marmoset Monkeys Following Administration of Felzartamab., PMID:39526914
The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLC., PMID:39521434
Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial., PMID:39475591
TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer., PMID:39469838
Central Memory CD4 T Cells from Persons with HIV Accumulate DNA Content Defects During Proliferative Response., PMID:39466061
For research use only. Not for human or drug use.
